CONTEXT THERAPEUTICS INC (CNTX)

Company Profile

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. The company is headquartered in Philadelphia, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2021-10-20. The firm is building an advanced portfolio of clinical-stage T cell engaging bispecific therapeutics, including CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody, and CT-95, a potential first-in-class mesothelin x CD3 bispecific antibody. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, endometrial, testicular, and lung, and absent from or expressed at low levels in healthy adult tissues. CTIM-76 is capable of binding to tumor cells expressing CLDN6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement while silent elsewhere. CTIM-76 has the potential for a wide therapeutic window. The Company’s CT-95 is being developed as a therapy for advanced cancers associated with mesothelin (MSLN) expression.

Company Info

CONTEXT THERAPEUTICS INC

2001 Market Street, Suite 3915 Unit #15

PHILADELPHIA PENNSYLVANIA

P: 12672257416

Employees: 5

Website: https://www.contexttherapeutics.com/